These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 23486421)

  • 41. An unusual case of haemolytic uraemic syndrome following endoscopic retrograde cholangiopancreatography rapidly improved with eculizumab.
    Taton O; Delhaye M; Stordeur P; Goodship T; Le Moine A; Massart A
    Acta Gastroenterol Belg; 2016; 79(2):257-61. PubMed ID: 27382949
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.
    Giordano P; Netti GS; Santangelo L; Castellano G; Carbone V; Torres DD; Martino M; Sesta M; Di Cuonzo F; Resta MC; Gaeta A; Milella L; Chironna M; Germinario C; Scavia G; Gesualdo L; Giordano M
    Pediatr Nephrol; 2019 Mar; 34(3):517-527. PubMed ID: 30362078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
    Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
    [TBL] [Abstract][Full Text] [Related]  

  • 44. STEC-HUS, atypical HUS and TTP are all diseases of complement activation.
    Noris M; Mescia F; Remuzzi G
    Nat Rev Nephrol; 2012 Nov; 8(11):622-33. PubMed ID: 22986360
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hemolytic Uremic Syndrome and Kidney Transplantation: A Case Series and Review of the Literature.
    Milan Manani S; Virzì GM; Giuliani A; Clementi A; Brocca A; Dissegna D; Martino F; d''Amore ESG; Ronco C
    Nephron; 2017; 136(3):245-253. PubMed ID: 28419995
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab.
    Servais A; Devillard N; Frémeaux-Bacchi V; Hummel A; Salomon L; Contin-Bordes C; Gomer H; Legendre C; Delmas Y
    Nephrol Dial Transplant; 2016 Dec; 31(12):2122-2130. PubMed ID: 27587606
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence.
    Levi C; Frémeaux-Bacchi V; Zuber J; Rabant M; Devriese M; Snanoudj R; Scemla A; Amrouche L; Mejean A; Legendre C; Sberro-Soussan R
    Transplantation; 2017 Dec; 101(12):2924-2930. PubMed ID: 28858176
    [TBL] [Abstract][Full Text] [Related]  

  • 49. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
    Garg N; Zhang Y; Nicholson-Weller A; Khankin EV; Borsa NG; Meyer NC; McDermott S; Stillman IE; Rennke HG; Smith RJ; Pavlakis M
    Nephrol Dial Transplant; 2018 Dec; 33(12):2260-2265. PubMed ID: 29370420
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome.
    Keating GM
    Drugs; 2013 Dec; 73(18):2053-66. PubMed ID: 24249647
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab.
    Gitiaux C; Krug P; Grevent D; Kossorotoff M; Poncet S; Eisermann M; Oualha M; Boddaert N; Salomon R; Desguerre I
    Dev Med Child Neurol; 2013 Aug; 55(8):758-65. PubMed ID: 23659643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.
    Schmidtko J; Peine S; El-Housseini Y; Pascual M; Meier P
    Am J Kidney Dis; 2013 Feb; 61(2):289-99. PubMed ID: 23141475
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
    Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Atypical hemolytic uremic syndrome.
    Kavanagh D; Goodship TH
    Curr Opin Hematol; 2010 Sep; 17(5):432-8. PubMed ID: 20613506
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
    Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry.
    Kielstein JT; Beutel G; Fleig S; Steinhoff J; Meyer TN; Hafer C; Kuhlmann U; Bramstedt J; Panzer U; Vischedyk M; Busch V; Ries W; Mitzner S; Mees S; Stracke S; Nürnberger J; Gerke P; Wiesner M; Sucke B; Abu-Tair M; Kribben A; Klause N; Schindler R; Merkel F; Schnatter S; Dorresteijn EM; Samuelsson O; Brunkhorst R;
    Nephrol Dial Transplant; 2012 Oct; 27(10):3807-15. PubMed ID: 23114903
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Typical or Atypical Hemolytic Uremic Syndrome and the Use of Eculizumab: 4 Illustrative Cases.
    de Ville de Goyet M; Detaille T; Godefroid N
    J Pediatr Hematol Oncol; 2019 Oct; 41(7):e459-e462. PubMed ID: 30933023
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM; Arias M; Ariceta G; Blasco M; Espinosa M; Grinyó JM; Praga M; Torra R; Vilalta R; Rodríguez de Córdoba S
    Nefrologia; 2013 Jan; 33(1):27-45. PubMed ID: 23364625
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report.
    Châtelet V; Lobbedez T; Frémeaux-Bacchi V; Ficheux M; Ryckelynck JP; Hurault de Ligny B
    Transplant Proc; 2010 Dec; 42(10):4353-5. PubMed ID: 21168697
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of eculizumab in renal transplantation.
    Barnett AN; Asgari E; Chowdhury P; Sacks SH; Dorling A; Mamode N
    Clin Transplant; 2013; 27(3):E216-29. PubMed ID: 23516966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.